Can a new drug called ROSE12 help fight advanced solid tumors?

NCT ID NCT05907980

Recruiting now Disease control Sponsor: Chugai Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look for early signs of anti-tumor activity. The study includes dose escalation, biomarker analysis, and expansion phases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called ROSE12, given alone or with atezolizumab or pembrolizumab
What this could lead to: If safe and effective, ROSE12 could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial focused on safety and dosing, so it is too soon to know if ROSE12 will work. Side effects are possible, and the drug may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Aichi Cancer Center
RECRUITING

Nagoya, Aichi-ken, 464-8681, Japan
Kanagawa Cancer Center
RECRUITING

Yokohama, Kanagawa, 241-8515, Japan
Kansai Medical University Hospital
RECRUITING

Hirakata-shi, Osaka, 573-1191, Japan
Kindai University Hospital
RECRUITING

Sakai-shi, Osaka, 590-0197, Japan
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa-shi, Chiba, 277-8577, Japan
Osaka International Cancer Institute
RECRUITING

Osaka, Osaka, 541-8567, Japan
Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Shizuoka Cancer Center
RECRUITING

Nagaizumi-chō, Shizuoka, 411-8777, Japan
The Cancer Institute Hospital of JFCR
RECRUITING

Koto-Ku, Tokyo, 135-8550, Japan
University of Pennsylvania Perelman Center for Advanced Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.